Public Health Impact After the Introduction of PsA-TT: The First 4 Years

Background. During the first introduction of a group A meningococcal vaccine (PsA-TT) in 2010–2011 and its rollout from 2011 to 2013, >150 million eligible people, representing 12 hyperendemic meningitis countries, have been vaccinated. Methods. The new vaccine effectiveness evaluation framework...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Clin Infect Dis
Главные авторы: Diomandé, Fabien V. K., Djingarey, Mamoudou H., Daugla, Doumagoum M., Novak, Ryan T., Kristiansen, Paul A., Collard, Jean-Marc, Gamougam, Kadidja, Kandolo, Denis, Mbakuliyemo, Nehemie, Mayer, Leonard, Stuart, James, Clark, Thomas, Tevi-Benissan, Carol, Perea, William A., Preziosi, Marie-Pierre, Marc LaForce, F., Caugant, Dominique, Messonnier, Nancy, Walker, Oladapo, Greenwood, Brian
Формат: Artigo
Язык:Inglês
Опубликовано: Oxford University Press 2015
Предметы:
The Meningitis Vaccine Project: The Development, Licensure, Introduction, and Impact of a New Group a Meningococcal Conjugate Vaccine for Africa
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4639484/
https://ncbi.nlm.nih.gov/pubmed/26553676
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/civ499
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы